Literature DB >> 10090684

Indications for and results of combined modality treatment of colorectal cancer.

L L Gunderson1.   

Abstract

Combined modality chemoirradiation is commonly used as a component of treatment in combination with maximum resection for both high-risk resectable and locally advanced primary or recurrent rectal cancers. With surgically resected but high-risk rectal cancers, postoperative chemoirradiation has been shown to improve both disease control (local and distant) and survival (disease-free and overall) and was recommended as standard adjuvant treatment at the 1990 National Institute of Health (NIH) Consensus Conference on Adjuvant treatment for patients with rectal and colon cancers. Subsequent intergroup trials are being conducted to help define optimal combinations of postoperative chemoirradiation for resected high-risk rectal cancers and to test sequencing issues of preoperative versus postoperative chemoirradiation. With locally unresectable primary or recurrent colorectal cancers, standard therapy with surgery, external beam irradiation (EBRT) and chemotherapy is often unsuccessful. When intraoperative electron irradiation (IOERT) is combined with standard treatment, local control and survival appear to be improved in separate analyses from the Mayo Clinic and the Massachusetts General Hospital (MGH). However, routine use of systemic therapy is also needed as a component of treatment, in view of high rates of systemic failure.

Entities:  

Mesh:

Year:  1999        PMID: 10090684     DOI: 10.1080/028418699431753

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Resectability of rectal cancers still fixed after radio-chemotherapy: evaluation by digital rectal examination, MRI, and intraoperative examination.

Authors:  G Baatrup; P Pfeiffer; Birgitte Svolgaard; H A Jensen
Journal:  Int J Colorectal Dis       Date:  2005-06-21       Impact factor: 2.571

2.  Pre-operative radiochemotherapy of locally advanced rectal cancer.

Authors:  Xiao-Nan Sun; Qi-Chu Yang; Jian-Bin Hu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

Review 4.  Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer.

Authors:  Rolf Sauer
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

5.  Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

6.  Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status.

Authors:  Leonard L Gunderson; Matthew Callister; Robert Marschke; Tonia Young-Fadok; Jacques Heppell; Jonathan Efron
Journal:  Gastrointest Cancer Res       Date:  2008-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.